Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Feb;25(2):281–282. doi: 10.1128/aac.25.2.281

Ketoconazole in the prevention of experimental candidal vaginitis.

J D Sobel, G Muller
PMCID: PMC185491  PMID: 6324671

Abstract

The prophylactic and therapeutic activities of ketoconazole were evaluated in rats inoculated intravaginally with Candida albicans. Daily doses of 2.5 mg/kg initiated 48 h before challenge and continued for 48 h thereafter protected 80% of the rats against infection. A similar result in rats with established infection was attained with daily doses of 5.0 mg/kg.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bisschop M. P., Merkus J. M., Scheygrond H., Van Cutsem J., van de Kuy A. Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic. Eur J Obstet Gynecol Reprod Biol. 1979 Aug;9(4):253–259. doi: 10.1016/0028-2243(79)90065-0. [DOI] [PubMed] [Google Scholar]
  2. Borgers M., Van den Bossche H., De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am J Med. 1983 Jan 24;74(1B):2–8. doi: 10.1016/0002-9343(83)90507-7. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES